Pulmatrix (PULM) Cash from Investing Activities (2014 - 2024)
Pulmatrix (PULM) posted Cash from Investing Activities of -$244000.0 for Q2 2024, down 58.44% sequentially from -$154000.0 in Q1 2024.
Pulmatrix (PULM) Cash from Investing Activities (2014 - 2024) Analysis & Trends
Pulmatrix has reported Cash from Investing Activities for 11 years, with the latest figure at -$244000.0 in Q2 2024.
- Quarterly Cash from Investing Activities changed N/A year-over-year to -$244000.0 in Q2 2024, while the trailing twelve-month figure through Dec 2024 was -$398000.0 (up 36.52% YoY) and the FY2024 annual result came in at -$398000.0, up 41.12% from the prior year.
- Cash from Investing Activities declined to -$244000.0 in Q2 2024 per PULM's latest filing, from -$154000.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at -$2000.0 in Q2 2020 and troughed at -$313000.0 in Q3 2023.
- A 5-year average of -$116076.9 and a median of -$96000.0 in 2020 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2020 and 2023: Cash from Investing Activities jumped 92.0% in 2020, then plunged 3288.89% in 2023.
- Over 5 years, Cash from Investing Activities stood at -$83000.0 in 2020, then surged by 68.67% to -$26000.0 in 2021, then jumped by 65.38% to -$9000.0 in 2022, then slumped by 3288.89% to -$305000.0 in 2023, then rose by 20.0% to -$244000.0 in 2024.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$244000.0, -$154000.0, and -$305000.0 for Q2 2024, Q1 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Pulmatrix | 5.46 Mn | 5.46 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -244,000.00 |
| Jun 30, 2024 | -244,000.00 |
| Mar 31, 2024 | -154,000.00 |
| Mar 31, 2024 | -154,000.00 |
| Dec 31, 2023 | -305,000.00 |
| Dec 31, 2023 | -305,000.00 |
| Sep 30, 2023 | -313,000.00 |
| Sep 30, 2023 | -313,000.00 |
| Dec 31, 2022 | -9,000.00 |
| Dec 31, 2022 | -9,000.00 |
| Jun 30, 2022 | -67,000.00 |
| Jun 30, 2022 | -67,000.00 |
| Mar 31, 2022 | -10,000.00 |
| Mar 31, 2022 | -10,000.00 |
| Dec 31, 2021 | -26,000.00 |
| Dec 31, 2021 | -26,000.00 |
| Sep 30, 2021 | -100,000.00 |
| Sep 30, 2021 | -100,000.00 |
| Dec 31, 2020 | -83,000.00 |
| Dec 31, 2020 | -83,000.00 |